1
|
Sano R, Fukuda H, Kubo R, Oishi T, Miyabe-Nishiwaki T, Kaneko A, Masato H, Takahashi Y, Hayakawa A, Yazawa S, Kominato Y. Emergence of an erythroid cell-specific regulatory region in ABO intron 1 attributable to A- or B-antigen expression on erythrocytes in Hominoidea. Sci Rep 2023; 13:4947. [PMID: 36973299 PMCID: PMC10043005 DOI: 10.1038/s41598-023-31961-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 03/20/2023] [Indexed: 03/29/2023] Open
Abstract
A- and B-antigens are present on red blood cells (RBCs) as well as other cells and secretions in Hominoidea including humans and apes such as chimpanzees and gibbons, whereas expression of these antigens on RBCs is subtle in monkeys such as Japanese macaques. Previous studies have indicated that H-antigen expression has not completely developed on RBCs in monkeys. Such antigen expression requires the presence of H-antigen and A- or B-transferase expression in cells of erythroid lineage, although whether or not ABO gene regulation is associated with the difference of A- or B-antigen expression between Hominoidea and monkeys has not been examined. Since it has been suggested that ABO expression on human erythrocytes is dependent upon an erythroid cell-specific regulatory region or the + 5.8-kb site in intron 1, we compared the sequences of ABO intron 1 among non-human primates, and demonstrated the presence of sites orthologous to the + 5.8-kb site in chimpanzees and gibbons, and their absence in Japanese macaques. In addition, luciferase assays revealed that the former orthologues enhanced promoter activity, whereas the corresponding site in the latter did not. These results suggested that the A- or B-antigens on RBCs might be ascribed to emergence of the + 5.8-kb site or the corresponding regions in ABO through genetic evolution.
Collapse
Affiliation(s)
- Rie Sano
- Department of Legal Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-Machi, Maebashi, 371-8511, Japan.
| | - Haruki Fukuda
- Department of Legal Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-Machi, Maebashi, 371-8511, Japan
| | - Rieko Kubo
- Department of Legal Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-Machi, Maebashi, 371-8511, Japan
| | - Takao Oishi
- Center for the Evolutionary Origins of Human Behavior, Kyoto University, Inuyama, Japan
| | | | - Akihisa Kaneko
- Center for the Evolutionary Origins of Human Behavior, Kyoto University, Inuyama, Japan
| | | | - Yoichiro Takahashi
- Department of Legal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - Akira Hayakawa
- Department of Legal Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-Machi, Maebashi, 371-8511, Japan
| | - Shin Yazawa
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - Yoshihiko Kominato
- Department of Legal Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-Machi, Maebashi, 371-8511, Japan
| |
Collapse
|
2
|
Fennell K, Keller MA, Villa MA, Paccapelo C, Kucerakova M, Rosochova J, Clemente DosSantos C, Brackney L, Lee CJ, Metcalf R, Crovetti G, Barbieri M, Travali S, Barrotta G, Giuca G, Guerra LE, Ochoa-Garay G. New ABO intron 1 variant alleles. Immunohematology 2021; 37:178-184. [PMID: 34964317 DOI: 10.21307/immunohematology-2021-029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Unusual and discrepant ABO phenotypes are often due to genetic variants that lead to altered levels or activity of ABO transferases and consequently to altered expression of ABO antigens. This report describes eight genetic alterations found in 15 cases with reduced or undetectable expression of ABO antigens. Forward and reverse ABO grouping was performed by standard gel or tube methods. Adsorption-heat elution and saliva testing for H and A substances followed the AABB technical manual procedures. Genomic DNA extracted from whole blood was PCR-amplified to cover the entire ABO coding sequence, splice junctions, proximal promoter, and intron 1 enhancer. Amplification products were sequenced by next-generation or Sanger dideoxy methods, either directly or after cloning into a bacterial plasmid vector. Eight unreported alleles were found in the 15 cases analyzed. Alleles ABO*A(28+1C) and ABO*A(29-5G) harbor variants that alter the consensus sequence at the intron 1 donor and acceptor splice sites, respectively. The other alleles harbor variants that alter the consensus sequence at transcription factor-binding sites in the intron 1 enhancer: specifically, ABO*A(28+5792T), ABO*A(28+5859A), and ABO*A(28+5860G) at GATA-1 sites; ABO*B(28+5877T) and ABO*B(28+5878G) at a RUNX1 site; and ABO*A(28+5843A) at or near a C/EBP site. Molecular and serologic characterization of ABO alleles can help in their future identification and in the resolution of discrepancies. Unusual and discrepant ABO phenotypes are often due to genetic variants that lead to altered levels or activity of ABO transferases and consequently to altered expression of ABO antigens. This report describes eight genetic alterations found in 15 cases with reduced or undetectable expression of ABO antigens. Forward and reverse ABO grouping was performed by standard gel or tube methods. Adsorption-heat elution and saliva testing for H and A substances followed the AABB technical manual procedures. Genomic DNA extracted from whole blood was PCR-amplified to cover the entire ABO coding sequence, splice junctions, proximal promoter, and intron 1 enhancer. Amplification products were sequenced by next-generation or Sanger dideoxy methods, either directly or after cloning into a bacterial plasmid vector. Eight unreported alleles were found in the 15 cases analyzed. Alleles ABO*A(28+1C) and ABO*A(29–5G) harbor variants that alter the consensus sequence at the intron 1 donor and acceptor splice sites, respectively. The other alleles harbor variants that alter the consensus sequence at transcription factor–binding sites in the intron 1 enhancer: specifically, ABO*A(28+5792T), ABO*A(28+5859A), and ABO*A(28+5860G) at GATA-1 sites; ABO*B(28+5877T) and ABO*B(28+5878G) at a RUNX1 site; and ABO*A(28+5843A) at or near a C/EBP site. Molecular and serologic characterization of ABO alleles can help in their future identification and in the resolution of discrepancies.
Collapse
Affiliation(s)
- K Fennell
- Laboratory Manager, Thermo Fisher Scientific , Austin, TX
| | - M A Keller
- Executive at American Red Cross Biomedical Services , Philadelphia, PA
| | - M A Villa
- Retired from Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico , Milan , Italy
| | - C Paccapelo
- Cinzia Paccapelo, SDc Biology, Senior Assistant in Immunohematology, Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico , Milan , Italy
| | - M Kucerakova
- Head, Department of Hematology and Blood Bank Narodna Transfuzna Sluzba SR , Bratislava , Slovakia
| | - J Rosochova
- Specialist in Transfusion Medicine, Narodna Transfuzna Sluzba SR , Bratislava , Slovakia
| | | | - L Brackney
- Medical Director of Blood Bank, Elmhurst Memorial Hospital , Elmhurst, IL
| | - C J Lee
- Assistant Professor of Internal Medicine, University of Utah Health , Salt Lake City , UT
| | - R Metcalf
- Medical Director of Transfusion Service, University of Utah Health , Salt Lake City, UT
| | - G Crovetti
- Medical Director, Immunoematologia e Centro Trasfusionale , ASST Valle Olona , Italy
| | - M Barbieri
- Lab Technician, Immunoematologia e Centro Trasfusionale , ASST Valle Olona , Italy
| | - S Travali
- Biologist, Laboratory Director, Servizio di Immunoematologia e Medicina Trasfusionale , Ragusa , Italy
| | - G Barrotta
- Biologist, Executive Biologist, Servizio di Immunoematologia e Medicina Trasfusionale , Ragusa , Italy
| | - G Giuca
- Biologist, Executive Biologist, Servizio di Immunoematologia e Medicina Trasfusionale , Ragusa , Italy
| | - L E Guerra
- Immunohematologist, Independent Consultant , Wimberly , TX
| | - G Ochoa-Garay
- New York Blood Center , 45-01 Vernon Boulevard, Long Island City , NY 11101
| |
Collapse
|
3
|
Kim TY, Yu H, Seo JY, Cho D. Molecular basis of weak A subgroups in the Korean population: Identification of three novel subgroup-causing variants in the ABO regulatory regions. Transfusion 2021; 62:286-291. [PMID: 34786713 DOI: 10.1111/trf.16730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Revised: 10/04/2021] [Accepted: 10/24/2021] [Indexed: 11/28/2022]
Abstract
BACKGROUND Recent studies on Chinese and Japanese populations have shown that weak ABO subgroups could be caused by variants in the major regulatory regions of ABO, the proximal promoter, +5.8-kb site, and CCAAT-binding factor/NF-Y binding site. We investigated the molecular basis of weak A subgroups in the Korean population. STUDY DESIGN AND METHODS This study included 11 samples suspected to have a weak A subgroup. These samples were subjected to sequencing analysis of ABO exons 6 and 7. If no subgroup-causing variants were detected in this region, exons 1-5 and three major regulatory regions were sequenced. RESULTS Sequencing analysis of exons 6 and 7 detected two known subgroup alleles (ABO*AW.10, n = 5; ABO*AEL.02, n = 2). The remaining four samples contained a sequence variant in the proximal promoter (g.4944C>T, n = 1; g.4954G>T, n = 1) or +5.8-kb site (g.10843T>C, n = 1; g.10935C>T, n = 1). Notably, three of the four variants (g.4944C>T, g.4954G>T, and g.10843T>C) have not been reported previously in weak ABO subgroups. CONCLUSION This study provides the first evidence that alterations in the proximal promoter and + 5.8-kb site could account for a substantial proportion of weak A subgroups in the Korean population.
Collapse
Affiliation(s)
- Tae Yeul Kim
- Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - HongBi Yu
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea
| | - Ji Young Seo
- Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Duck Cho
- Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.,Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea.,Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon, Republic of Korea
| |
Collapse
|
4
|
A historical overview of advances in molecular genetic/genomic studies of the ABO blood group system. Glycoconj J 2021; 39:207-218. [PMID: 34757541 PMCID: PMC8578530 DOI: 10.1007/s10719-021-10028-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2021] [Revised: 10/18/2021] [Accepted: 10/20/2021] [Indexed: 10/30/2022]
Abstract
In 1990, 90 years after the discovery of ABO blood groups by Karl Landsteiner, my research team at the Molecular Biology Laboratory of the now-defunct Biomembrane Institute elucidated the molecular genetic basis of the ABO polymorphism. Henrik Clausen, Head of the Immunology Laboratory, initiated the project by isolating human group A transferase (AT), whose partial amino acid sequence was key to its success. Sen-itiroh Hakomori, the Scientific Director, provided all the institutional support. The characterization started from the 3 major alleles (A1, B, and O), and proceeded to the alleles of A2, A3, Ax and B3 subgroups and also to the cis-AB and B(A) alleles, which specify the expression of A and B antigens by single alleles. In addition to the identification of allele-specific single nucleotide polymorphism (SNP) variations, we also experimentally demonstrated their functional significance in glycosyltransferase activity and sugar specificity of the encoded proteins. Other scientists interested in blood group genes later characterized more than 250 ABO alleles. However, recent developments in next-generation sequencing have enabled the sequencing of millions of human genomes, transitioning from the era of genetics to the era of genomics. As a result, numerous SNP variations have been identified in the coding and noncoding regions of the ABO gene, making ABO one of the most studied loci for human polymorphism. As a tribute to Dr. Hakomori's scientific legacy, a historical overview in molecular genetic/genomic studies of the human ABO gene polymorphism is presented, with an emphasis on early discoveries made at his institute.
Collapse
|
5
|
Yu H, Kim TY, Moon SJ, Chung YN, Yoo HJ, Kim JH, Cho D. Sequence variants in the proximal promoter and +5.8-kb site of ABO in Koreans with weak B phenotypes. Vox Sang 2021; 117:442-446. [PMID: 34651317 DOI: 10.1111/vox.13207] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 06/11/2021] [Accepted: 09/06/2021] [Indexed: 12/01/2022]
Abstract
BACKGROUND AND OBJECTIVES Several studies on Chinese and Japanese populations have revealed that a substantial proportion of weak B subgroups are caused by variants in the major regulatory regions of ABO, the proximal promoter, CCAAT-binding factor/NF-Y binding site and +5.8-kb site. We performed molecular analyses of these regions in Koreans with weak B phenotypes. MATERIALS AND METHODS This study included 16 samples with weak B phenotypes (4 B3 , 1 Bw , 5 A1 B3 and 6 A1 Bw ) harbouring no subgroup-causing variants in ABO exons 6 and 7. These samples were subjected to sequencing analysis of exons 1-5 and the major regulatory regions of ABO. RESULTS Of the 16 samples, 14 were found to carry a sequence variant either in the proximal promoter (g.4991_5008del [n = 3]) or the +5.8-kb site (g.10893G>A [n = 4] and g.10925C>T [n = 7]). The remaining two samples were found to contain no subgroup-causing variants. CONCLUSION Our study demonstrates that sequence variants in the proximal promoter and +5.8-kb site account for a substantial proportion of weak B subgroups in Koreans, suggesting that molecular analysis of these regions is essential for the accurate determination of ABO genotypes in Koreans with weak B phenotypes.
Collapse
Affiliation(s)
- HongBi Yu
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, South Korea
| | - Tae Yeul Kim
- Department of Laboratory Medicine and Genetics, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - Sue Jin Moon
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, South Korea
| | - Yoo Na Chung
- Department of Laboratory Medicine, Dankook University Hospital, Cheonan, South Korea
| | - Hwa Jong Yoo
- Department of Laboratory Medicine and Genetics, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - Jeong Hoon Kim
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, South Korea
| | - Duck Cho
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, South Korea
- Department of Laboratory Medicine and Genetics, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, South Korea
| |
Collapse
|
6
|
A cell-specific regulatory region of the human ABO blood group gene regulates the neighborhood gene encoding odorant binding protein 2B. Sci Rep 2021; 11:7325. [PMID: 33795748 PMCID: PMC8016878 DOI: 10.1038/s41598-021-86843-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Accepted: 03/22/2021] [Indexed: 01/27/2023] Open
Abstract
The human ABO blood group system is of great importance in blood transfusion and organ transplantation. ABO transcription is known to be regulated by a constitutive promoter in a CpG island and regions for regulation of cell-specific expression such as the downstream + 22.6-kb site for epithelial cells and a site in intron 1 for erythroid cells. Here we investigated whether the + 22.6-kb site might play a role in transcriptional regulation of the gene encoding odorant binding protein 2B (OBP2B), which is located on the centromere side 43.4 kb from the + 22.6-kb site. In the gastric cancer cell line KATOIII, quantitative PCR analysis demonstrated significantly reduced amounts of OBP2B and ABO transcripts in mutant cells with biallelic deletions of the site created using the CRISPR/Cas9 system, relative to those in the wild-type cells, and Western blotting demonstrated a corresponding reduction of OBP2B protein in the mutant cells. Moreover, single-molecule fluorescence in situ hybridization assays indicated that the amounts of both transcripts were correlated in individual cells. These findings suggest that OBP2B could be co-regulated by the + 22.6-kb site of ABO.
Collapse
|
7
|
Kominato Y, Sano R, Takahashi Y, Hayakawa A, Ogasawara K. Human ABO gene transcriptional regulation. Transfusion 2020; 60:860-869. [PMID: 32216153 PMCID: PMC7187371 DOI: 10.1111/trf.15760] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2019] [Revised: 02/06/2020] [Accepted: 02/23/2020] [Indexed: 12/18/2022]
Affiliation(s)
- Yoshihiko Kominato
- Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Rie Sano
- Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Yoichiro Takahashi
- Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Akira Hayakawa
- Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | | |
Collapse
|
8
|
Hayakawa A, Sano R, Takahashi Y, Kubo R, Harada M, Omata M, Yokohama A, Handa H, Tsukada J, Takeshita H, Tsuneyama H, Ogasawara K, Kominato Y. RUNX1 mutation in a patient with myelodysplastic syndrome and decreased erythrocyte expression of blood group A antigen. Transfusion 2019; 60:184-196. [PMID: 31840280 DOI: 10.1111/trf.15628] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2019] [Revised: 09/30/2019] [Accepted: 11/01/2019] [Indexed: 12/30/2022]
Abstract
BACKGROUND Loss of blood group ABO antigens on red blood cells (RBCs) is well known in patients with leukemias, and such decreased ABO expression has been reported to be strongly associated with hypermethylation of the ABO promoter. We investigated the underlying mechanism responsible for A-antigen reduction on RBCs in a patient with myelodysplastic syndrome. STUDY DESIGN AND METHODS Genetic analysis of ABO was performed by PCR and sequencing using peripheral blood. RT-PCR were carried out using cDNA prepared from total bone marrow (BM) cells. Bisulfite genomic sequencing was performed using genomic DNA from BM cells. Screening of somatic mutations was carried out using a targeted sequencing panel with genomic DNA from BM cells, followed by transient transfection assays. RESULTS Genetic analysis of ABO did not reveal any mutation in coding regions, splice sites, or regulatory regions. RT-PCR demonstrated reduction of A-transcripts when the patient's RBCs were not agglutinated by anti-A antibody and did not indicate any significant increase of alternative splicing products in the patient relative to the control. DNA methylation of the ABO promoter was not obvious in erythroid cells. Targeted sequencing identified somatic mutations in ASXL1, EZH2, RUNX1, and WT1. Experiments involving transient transfection into K562 cells showed that the expression of ABO was decreased by expression of the mutated RUNX1. CONCLUSION Because the RUNX1 mutation encoded an abnormally elongated protein without a transactivation domain which could act as dominant negative inhibitor, this frame-shift mutation in RUNX1 may be a genetic candidate contributing to A-antigen loss on RBCs.
Collapse
Affiliation(s)
- Akira Hayakawa
- Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Rie Sano
- Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Yoichiro Takahashi
- Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Rieko Kubo
- Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Megumi Harada
- Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Masato Omata
- Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | | | - Hiroshi Handa
- Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Junichi Tsukada
- Department of Hematology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Haruo Takeshita
- Department of Legal Medicine, Shimane University School of Medicine, Izumo, Japan
| | | | | | - Yoshihiko Kominato
- Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| |
Collapse
|
9
|
Ying YL, Hong XZ, Xu XG, Chen S, He J, Zhu FM, Xie XY. Molecular Basis of ABO Variants Including Identification of 16 Novel ABO Subgroup Alleles in Chinese Han Population. Transfus Med Hemother 2019; 47:160-166. [PMID: 32355476 DOI: 10.1159/000501862] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2019] [Accepted: 07/01/2019] [Indexed: 02/03/2023] Open
Abstract
Introduction The characteristic of ABO blood subgroup is crucial for elucidating the mechanisms of such variant phenotypes and offering useful information in blood transfusion. Methods In total, 211 ABO variants including part of available family members were investigated in this study. The phenotypes of these individuals were typed with serologic methods. The full coding regions of ABO gene and the erythroid cell-specific regulatory elements in intron 1 of them were amplified with polymerase chain reaction and then directly sequenced. The novel alleles were confirmed by cloning and sequencing. Phylogenetic tree was made using CLUSTAL W software. 3D structural analyses of the glycosyltransferases (GTs) with some typical mutations were performed by PyMOL software. Results Forty-eight distinctly rare ABO alleles were identified in 211 Chinese variant individuals, including 16 novel ABO alleles. All of the alleles were categorized as 5 groups: 16 ABO*A alleles, 23 ABO*B alleles, 4 ABO*BA alleles, 4 ABO*cisAB alleles, and 1 ABO*O alleles. ABO*A2.08 and ABO*BA.02 were the relatively predominant A and B subgroup alleles, respectively. According to the phylogenetic tree, 28 alleles (5 common alleles and 23 alleles identified in our laboratory) were classified into 3 major allelic lineages. The structural analysis of 3D homology modeling predicted reduced protein stability of the mutant GTs and may explain the reduced ABO antigen expression. Conclusions The molecular basis of ABO variants was analyzed, and 16 novel ABO alleles were identified. The results extended the information of ABO variants and provided a basis for better transfusion strategies and helped to improve blood transfusion safety.
Collapse
Affiliation(s)
- Yan-Ling Ying
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.,Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research of Zhejiang Province, Hangzhou, China
| | - Xiao-Zhen Hong
- Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research of Zhejiang Province, Hangzhou, China
| | - Xian-Guo Xu
- Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research of Zhejiang Province, Hangzhou, China
| | - Shu Chen
- Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research of Zhejiang Province, Hangzhou, China
| | - Ji He
- Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research of Zhejiang Province, Hangzhou, China
| | - Fa-Ming Zhu
- Blood Center of Zhejiang Province, Hangzhou, China.,Key Laboratory of Blood Safety Research of Zhejiang Province, Hangzhou, China
| | - Xin-You Xie
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
| |
Collapse
|
10
|
Ogasawara K, Miyazaki T, Ito S, Yabe R, Uchikawa M, Enomoto T, Yokoya N, Hori Y, Kumamoto M, Watanabe S, Satake M. The B allele with a 5·8 kb deletion in intron 1 of the ABO gene is the major allele in Japanese individuals with B m and A 1 B m phenotypes. Vox Sang 2018; 113:393-396. [PMID: 29473176 DOI: 10.1111/vox.12642] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2017] [Revised: 12/20/2017] [Accepted: 01/19/2018] [Indexed: 12/23/2022]
Abstract
Bm and A1 Bm phenotypes are the most frequent ABO variants in the Japanese population. The B antigen on Bm red blood cells is only detectable by adsorption and elution tests, and plasma B-transferase activity is usually detected at half or less levels compared with that of common B. Recently, a B allele lacking an erythroid cell-specific transcription enhancer in intron 1 of the ABO gene was identified from individuals with Bm and A1 Bm phenotypes, which could explain the unique serologic properties of Bm . In the Japanese Red Cross Society, eight Blood Centers tested blood samples from donors throughout Japan and collected blood samples from 888 Bm and 415 A1 Bm individuals. DNA analysis revealed that 1300 of 1303 (99·77%) individuals had the B allele with a 5·8 kb deletion (c.28 + 5110_10889del), which included the enhancer element.
Collapse
Affiliation(s)
- K Ogasawara
- Japanese Red Cross Central Blood Institute, Tokyo, Japan
| | - T Miyazaki
- Japanese Red Cross Hokkaido Block Blood Center, Hokkaido, Japan
| | - S Ito
- Japanese Red Cross Tohoku Block Blood Center, Miyagi, Japan
| | - R Yabe
- Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan
| | - M Uchikawa
- Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan
| | - T Enomoto
- Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Saitama, Japan
| | - N Yokoya
- Japanese Red Cross Tokai-Hokuriku Block Blood Center, Aichi, Japan
| | - Y Hori
- Japanese Red Cross Kinki Block Blood Center, Osaka, Japan
| | - M Kumamoto
- Japanese Red Cross Chu-Shikoku Block Blood Center, Hiroshima, Japan
| | - S Watanabe
- Japanese Red Cross Kyushu Block Blood Center, Fukuoka, Japan
| | - M Satake
- Japanese Red Cross Central Blood Institute, Tokyo, Japan
| |
Collapse
|
11
|
Möller M, Hellberg Å, Olsson ML. Thorough analysis of unorthodoxABOdeletions called by the 1000 Genomes project. Vox Sang 2017; 113:185-197. [DOI: 10.1111/vox.12613] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2017] [Revised: 10/23/2017] [Accepted: 10/24/2017] [Indexed: 01/15/2023]
Affiliation(s)
- M. Möller
- Department of Laboratory Medicine, Hematology and Transfusion Medicine; Lund University; Lund Sweden
| | - Å. Hellberg
- Department of Clinical Immunology and Transfusion Medicine; Laboratory Medicine Office of Medical Service; Region Skåne Sweden
| | - M. L. Olsson
- Department of Laboratory Medicine, Hematology and Transfusion Medicine; Lund University; Lund Sweden
- Department of Clinical Immunology and Transfusion Medicine; Laboratory Medicine Office of Medical Service; Region Skåne Sweden
| |
Collapse
|
12
|
Sano R, Nakajima T, Takahashi Y, Kubo R, Kobayashi M, Takahashi K, Takeshita H, Ogasawara K, Kominato Y. Epithelial Expression of Human ABO Blood Group Genes Is Dependent upon a Downstream Regulatory Element Functioning through an Epithelial Cell-specific Transcription Factor, Elf5. J Biol Chem 2016; 291:22594-22606. [PMID: 27587399 DOI: 10.1074/jbc.m116.730655] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Revised: 08/30/2016] [Indexed: 01/03/2023] Open
Abstract
The human ABO blood group system is of great importance in blood transfusion and organ transplantation. The ABO system is composed of complex carbohydrate structures that are biosynthesized by A- and B-transferases encoded by the ABO gene. However, the mechanisms regulating ABO gene expression in epithelial cells remain obscure. On the basis of DNase I-hypersensitive sites in and around ABO in epithelial cells, we prepared reporter plasmid constructs including these sites. Subsequent luciferase assays and histone modifications indicated a novel positive regulatory element, designated the +22.6-kb site, downstream from ABO, and this was shown to enhance ABO promoter activity in an epithelial cell-specific manner. Expression of ABO and B-antigen was reduced in gastric cancer KATOIII cells by biallelic deletion of the +22.6-kb site using the CRISPR/Cas9 system. Electrophoretic mobility shift assay and chromatin immunoprecipitation assay demonstrated that the site bound to an epithelial cell-specific transcription factor, Elf5. Mutation of the Ets binding motifs to abrogate binding of this factor reduced the regulatory activity of the +22.6-kb site. Furthermore, ELF5 knockdown with shRNA reduced both endogenous transcription from ABO and B-antigen expression in KATOIII cells. Thus, Elf5 appeared to be involved in the enhancer potential of the +22.6-kb site. These results support the contention that ABO expression is dependent upon a downstream positive regulatory element functioning through a tissue-restricted transcription factor, Elf5, in epithelial cells.
Collapse
Affiliation(s)
- Rie Sano
- From the Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, 371-8511 Japan,
| | - Tamiko Nakajima
- From the Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, 371-8511 Japan
| | - Yoichiro Takahashi
- From the Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, 371-8511 Japan
| | - Rieko Kubo
- From the Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, 371-8511 Japan
| | - Momoko Kobayashi
- From the Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, 371-8511 Japan
| | - Keiko Takahashi
- From the Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, 371-8511 Japan
| | - Haruo Takeshita
- the Department of Legal Medicine, Shimane University School of Medicine, Izumo, Japan, and
| | | | - Yoshihiko Kominato
- From the Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, 371-8511 Japan
| |
Collapse
|
13
|
Fox K, Johnsen JM, Coe BP, Frazar CD, Reiner AP, Eichler EE, Nickerson DA. Analysis of exome sequencing data sets reveals structural variation in the coding region ofABOin individuals of African ancestry. Transfusion 2016; 56:2744-2749. [DOI: 10.1111/trf.13797] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Revised: 07/06/2016] [Accepted: 07/07/2016] [Indexed: 12/26/2022]
Affiliation(s)
| | - Jill M. Johnsen
- Hematology Division; University of Washington, School of Medicine
- Bloodworks Northwest
| | | | | | - Alexander P. Reiner
- Public Health Sciences Division; Fred Hutchinson Cancer Research Center
- Department of Epidemiology; University of Washington, School of Public Health
| | - Evan E. Eichler
- Department of Genome Sciences
- Howard Hughes Medical Institute; Seattle Washington
| | | | | |
Collapse
|
14
|
Isa K, Yamamuro Y, Ogasawara K, Yabe R, Ogiyama Y, Ito S, Takahashi Y, Kominato Y, Sano R, Uchikawa M. Presence of nucleotide substitutions in the ABO promoter in individuals with phenotypes A3 and B3. Vox Sang 2015; 110:285-7. [PMID: 26529276 DOI: 10.1111/vox.12363] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2015] [Revised: 09/15/2015] [Accepted: 09/15/2015] [Indexed: 01/30/2023]
Abstract
Recently, the involvement of mutation and deletion of transcription regulatory elements in the Bm , Am , A3 and B3 phenotypes has been reported. In the present study, we carried out genetic analysis of individuals with A3 and B3 using peptide nucleic acid-clamping PCR to exclude amplification of O alleles. Two single-point mutations, -76G>C and -68G>T, were found in the ABO promoter on the A-allele in three A3 individuals and on the B allele in a B3 individual, respectively. Transient transfection of luciferase reporter plasmids carrying the same mutations into K562 cells revealed decreased luciferase activity in comparison with that carrying the wild-type promoter. These observations suggest that the mutations downregulate the promoter activity, leading to reduction in A- or B-antigen expression on red blood cells in individuals with the A3 and B3 phenotypes.
Collapse
Affiliation(s)
- K Isa
- Japanese Red Cross Central Blood Institute, Tokyo, Japan
| | - Y Yamamuro
- Japanese Red Cross Central Blood Institute, Tokyo, Japan
| | - K Ogasawara
- Japanese Red Cross Central Blood Institute, Tokyo, Japan
| | - R Yabe
- Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan
| | - Y Ogiyama
- Japanese Red Cross Touhoku Block Blood Center, Sendai, Japan
| | - S Ito
- Japanese Red Cross Touhoku Block Blood Center, Sendai, Japan
| | - Y Takahashi
- Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Y Kominato
- Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - R Sano
- Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - M Uchikawa
- Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan
| |
Collapse
|